Answers are grounded in this paper and cite their sources.
Purpose: To evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of SCAI-005-a topical ophthalmic solution of axitinib for neovascular age-related macular degeneration (AMD), a VEGF receptor tyrosine kinase inhibitor-following single and multiple ascending doses (SAD and MAD) in healthy Korean adults. Design: Randomized, double-masked, placebo-controlled, single- and multiple-ascending-dose phase I study. Subjects: Forty-eight healthy Korean adults were randomized 3:1 (active:placebo) into six cohorts across SAD (0.04% as a single drop, 0.08% as a single drop, and 0.08% as two drops) and MAD (0.04% 1 drop three times daily (TID), 0.08% 1-drop TID, and 0.08% two-drop TID for 7 days) groups. Methods: SCAI-005 or placebo was administered topically to 1 eye per subject. Serial blood samples were collected for systemic PK analysis using noncompartmental analysis. Safety was assessed through treatment-emergent adverse events (TEAEs), ophthalmic examinations, vital signs, electrocardiography, and clinical laboratory tests. Main Outcome Measures: ) and dose proportionality. Results: slope estimates were above unity in both cohorts (1.64-1.69) with confidence intervals not including unity. Conclusions: Topical SCAI-005 was generally well tolerated in this small first-in-human study in healthy Korean adults, producing low systemic axitinib exposure and no obvious short-term safety signal. These findings will require confirmation in phase II studies enrolling the target neovascular AMD population. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: